Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene

Kidney International

Volumn 55, Issue 4, 1999, Pages 1234-1240

  Osada, Shiwori ^a   Ebihara, Isao ^a,b   Setoguchi, Yasuhiro ^a,b   Takahashi, Hisahide ^a,b   Tomino, Yasuhiko ^a,b   Koide, Hikaru ^a,b,c  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c KOTO HOSPITAL   (Japan)

Author keywords

DBA 2FG pcy mouse; End stage renal disease; Gene therapy; Mesothelial cell; Polycystic kidney disease; Recombinant human erythropoietin

Indexed keywords

OLIGOSACCHARIDE; RECOMBINANT ERYTHROPOIETIN; VIRUS VECTOR;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DNA TRANSFER; DOSE TIME EFFECT RELATION; FEMALE; GENE THERAPY; HEMATOCRIT; HORMONE DETERMINATION; KIDNEY POLYCYSTIC DISEASE; MALE; MESOTHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0032895001     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00381.x     Document Type: Article

References (28)

1. KOURY MJ, BONDURANT MC: The molecular mechanism of erythropoietin action. Eur J Biochem 210:649-663, 1992
2. KOURY ST, BONDURANT MC, KOURY MJ: Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71:524-527, 1988
3. NISSENSON AR: National cooperative rHu erythropoietin study in patients with chronic renal failure: A phase IV multicenter study. Am J Kidney Dis 18(Suppl 1):24-33, 1991
4. GOLDWASSER E, KUNG CKH, ELIASON J: On the mechanism of erythropoietin-induccd differentiation: The role of sialic acid in erythropoietin action. J Biol Chem 249:4202-4206, 1974
5. IMAI N, HIGUCHI M, KAWAMURA A, TOMONOH K, OH-EDA M, FUHWARA M, SHIMONAKA Y, OCHI N: Physicochemical and biological characterization of asialoerythropoietin: Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem 194:457-462, 1990
6. ERSLEV AJ: Drug therapy. N Engl J Med 324:1339-1344, 1991
7. ESCHBACH JW, KELLY MR, HALEY NR, ABELS RI, ADAMSON JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
8. IFUDU O, FELDMAN J, FRIEDMAN EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334:420-425, 1996
9. HAMAMORI Y, SAMAL B, TIAN J, KEDES L: Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest 95:1808-1813, 1995
10. NAFFAKH N, HENRI A, VILLEVAL JL, ROUYER-FESSARD P, MOULLIER P, BLUMENFELD N, DANOS O, VAINCHENKER W, HEARD JM, BEUZARD Y: Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc Natl Acad Sci USA 92:3194-3198, 1995
11. DESCAMPS V, BLUMENFELD N, VILLEVAL J-L, VAINCHENKER W, PERRICAUDET M, BEUZARD Y: Erythropoietin gene transfer and expression in adult normal mice: Use of an adenovirus vector. Hum Gene Ther 5:979-985, 1994
12. SETOGUCHI Y, DANEL C, CRYSTAL RG: Stimulation of erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector. Blood 84:2946-2953, 1994
13. TRIPATHY SK, GOLDWASSER E, LU M-M, BARR E, LEIDEN JM: Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci USA 91:11557-11561, 1994
14. ZHOU L, DEY CR, WERT SE, DUVALL MD, FRIZZELL RA, WHITSETT JA: Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266:1705-1708, 1994
15. TAKAHASHI H, CALVET JP, DITTEMORE-HOOVER D, YOSHIDA K, GRANTHAM JJ, GATTONE VH: A hereditary model of slowly progressive polycystic kidney disease. J Am Soc Nephrol 1:980-989, 1991
16. KOUMEGAWA J, NAGANO N, ARAI H, WADA M, KUSAKA M, TAKAHASHI H: Anemia in new congenital adult type polycystic kidney mice. J Urol 146:1645-1649, 1991
17. SEGUCHI C, SHIMA T, MISAKI M, TAKARADA Y, OKAZAKI T: Serum erythropoietin concentrations and iron status in patients on chronic hemodialysis. Clin Chem 38:199-203, 1992
18. DANNENBERG M JR, SUGA M: Histochemical stains for macrophages in cell smears and tissue sections: β-galactosidase, acid phosphatase, nonspecific esterase, succinic dehydrogenase, and cytochrome oxidase, in Methods for Studying Mononuclear Phagocytes, edited by ADAMS DO, EDELSON PJ, KOREN H, San Diego, Academic Press, 1981, pp 375-396
19. CHOMCZYNSKI P, SACCHI N: Single-step method of RNA isolation by acid guanidine thiocyanate phenol chloroform extraction. Anal Biochem 162:156-159, 1987
20. SETOGUCHI Y, JAFFE HA, CHU CS, CRYSTAL RG: Intraperitoneal in vivo gene therapy to deliver al-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 10:369-377, 1994
21. TAKEUCHI M, KOBATA A: Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1:337-346, 1991
22. NIELSON OJ, SCHUSTER SJ, KAUFMAN R, ERSLEV AJ, CARO J: Regulation of erythropoietin production in a human hepatoblastoma cell line. Blood 70:1904-1909, 1987
23. CHANDRA M. MILLER ME, GARCIA JF, MOSSEY RT, MCVICAR M: Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron 39:26-29, 1985
24. PAVLOVIC-KENTERA V, CLEMONS GK, DJUKANOVIC L, BILJANOVIC-PAUNOVIC L: Erythropoietin and anemia in chronic renal failure. Exp Hematol 15:785-789, 1987
25. YANG Y, NUNES FA, BERENCSI K, FURTH EE, GONCZOL E, WILSON JM: Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407-4411, 1994
26. TRIPATHY SK, BLACK HB, GOLDWASSER E, LEIDEN JM: Immuneresponses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 2:545-550, 1996
27. GAO G-P, YANG Y, WILSON JM: Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 70:8934-8943, 1996
28. ILAN Y, DROGUEIT G, CHOWDHURY NR, LI Y, SENGUPTA K, THUMMALA NR, DAVIDSON A, CHOWDHURY JR, HORWITZ MS: Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits longterm gene expression. Proc Natl Acad Sci USA 94:2587-2592, 1997